Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

NCT05435248 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

354

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic NSCLC

Interventions

DRUG: HS-10375

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.